126 related articles for article (PubMed ID: 2768892)
21. Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma.
Tomás C; Penttinen J; Risteli J; Risteli L; Vuori J; Kauppila A
Cancer; 1990 Dec; 66(11):2399-406. PubMed ID: 2245396
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
Colomer R; Ruibal A; Salvador L
Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
[TBL] [Abstract][Full Text] [Related]
24. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
[TBL] [Abstract][Full Text] [Related]
25. CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Caponigro F; Iaffaioli RV; Pagliarulo C; De Placido S; Frasci G; Ungaro B; Matano E; Bianco AR
Int J Biol Markers; 1990; 5(2):73-6. PubMed ID: 2283480
[TBL] [Abstract][Full Text] [Related]
26. Differences in serum tumor markers between colon and rectal cancer. Comparison of CA 242 and carcinoembryonic antigen.
Carpelan-Holmström MA; Haglund CH; Roberts PJ
Dis Colon Rectum; 1996 Jul; 39(7):799-805. PubMed ID: 8674374
[TBL] [Abstract][Full Text] [Related]
27. Simple method for comparing reliability of two serum tumour markers in breast carcinoma.
O'Brien DP; Gough DB; Skehill R; Grimes H; Given HF
J Clin Pathol; 1994 Feb; 47(2):134-7. PubMed ID: 8132827
[TBL] [Abstract][Full Text] [Related]
28. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
[No Abstract] [Full Text] [Related]
29. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
Park BW; Oh JW; Kim JH; Park SH; Kim KS; Kim JH; Lee KS
Ann Oncol; 2008 Apr; 19(4):675-81. PubMed ID: 18037623
[TBL] [Abstract][Full Text] [Related]
30. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
[TBL] [Abstract][Full Text] [Related]
31. CA 549 as a marker in breast cancer.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC
Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307
[TBL] [Abstract][Full Text] [Related]
32. Combined detection of CEA, CA 19-9, CA 242 and CA 50 in the diagnosis and prognosis of resectable gastric cancer.
Tian SB; Yu JC; Kang WM; Ma ZQ; Ye X; Cao ZJ; Yan C
Asian Pac J Cancer Prev; 2014; 15(15):6295-300. PubMed ID: 25124614
[TBL] [Abstract][Full Text] [Related]
33. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
34. CA 15-3 in patients with locoregional and metastatic breast carcinoma.
Geraghty JG; Coveney EC; Sherry F; O'Higgins NJ; Duffy MJ
Cancer; 1992 Dec; 70(12):2831-4. PubMed ID: 1451063
[TBL] [Abstract][Full Text] [Related]
35. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
[TBL] [Abstract][Full Text] [Related]
36. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?
Saygili U; Guclu S; Uslu T; Erten O; Demir N; Onvural A
Gynecol Oncol; 2002 Jul; 86(1):57-61. PubMed ID: 12079301
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
38. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
Fritsche E; Benz J
Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
[TBL] [Abstract][Full Text] [Related]
39. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer.
Lian M; Zhang C; Zhang D; Chen P; Yang H; Yang Y; Chen S; Hong G
J Clin Lab Anal; 2019 Jun; 33(5):e22875. PubMed ID: 30843272
[TBL] [Abstract][Full Text] [Related]
40. CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases.
Bombardieri E; Pizzichetta M; Veronesi P; Seregni E; Bogni A; Maffioli L; Jotti GS; Bassetto MA; Zurrida S; Costa A
Eur J Cancer; 1992; 29A(1):144-6. PubMed ID: 1445733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
